GlaxoSmithKline Faces Bribery Allegations Yet Again, This Time in Iraq
GlaxoSmithKline plc (NYSE:GSK) is in the midst of investigating claims of bribery by its employees in the Middle East; an unnamed source familiar with Glaxo’s Middle East operations apparently emailed the company late to report “corrupt practices,” both last year and in 2012, according to The Wall Street Journal.
The British pharmaceutical giant is already undergoing an investigation by the Chinese government into similar corruption allegations there. Reportedly, Glaxo employees in China bribed physicians involved in clinical trials of Glaxo’s drugs; the company has since detained four of its senior Chinese staff, although none have been charged.
Glaxo said it began investigating the allegations in Iraq as soon as it became aware of them, The Wall Street Journal reports, and the investigations are ongoing. According to the source who brought the allegations before the company, Glaxo’s team in Iraq hired 16 government-employed physicians and pharmacists as paid sales representatives for the company.